Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of interleukin antibodies to preparation of pharmaceutical composition for treating endometriosis

A technology of interleukin and endometrium, applied in the direction of drug combination, antibody, immunoglobulin, etc., can solve the problems of increased nerve density, immune cells can not effectively remove endometrial cells, etc.

Inactive Publication Date: 2017-08-11
THE OBSTETRICS & GYNECOLOGY HOSPITAL OF FUDAN UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] The theory of menstrual blood reflux in the endometrium is the most recognized theory. However, menstrual blood reflux occurs in most women's menstrual cycles, but only 10% to 15% of women suffer from EMS; some studies have shown that endometrial stromal cells (ESC) Intrinsic abnormalities associated with EMS include abnormal gene expression, endometrial response to hormones, increased nerve density, and oxidative stress; under normal conditions, reflux of the endometrium into the pelvis is recognized by the body's immune system as The "foreign matter" has been removed, and in the pelvic and abdominal cavity of EMS patients, the local immune microenvironment is likely to have changed. The abnormal function of immune cells not only cannot effectively remove the ectopic endometrial cells, but even help them in the ectopic endometrium. Therefore, in recent years, more and more evidences have shown that the abnormal local immune microenvironment in the pelvic and abdominal cavity of EMS patients plays an indispensable role in the occurrence and development of EMS, especially the various immune cells in ectopic lesions. and the cytokines produced

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of interleukin antibodies to preparation of pharmaceutical composition for treating endometriosis
  • Application of interleukin antibodies to preparation of pharmaceutical composition for treating endometriosis
  • Application of interleukin antibodies to preparation of pharmaceutical composition for treating endometriosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Example 1 Analysis of IL-10, IL-17 and IL10 in the peritoneal fluid of EMS patients + Th17 cell level

[0045] First, the CBA (BD company) method was used to detect, and the results showed that, compared with the control group, in the EMS (I-II stage), that is, the early stage of the disease, the pro-inflammatory cytokine IL-17A was significantly increased; but in the EMS (III-IV stage). stage), that is, the anti-inflammatory cytokine IL-10 is significantly increased in the late stage of the disease (such as figure 1 Shown in A); then detect with flow cytometry (flow cytometry antibodies are all purchased from Biolegend company), the result shows, I-II stage EMS patient's peritoneal fluid IL-17A level increases significantly, but along with disease progression, no Trend to further increase, but stage III-IV patients have higher levels of IL-10 + Th17 cells (such as figure 1 B, 1C shown).

Embodiment 2

[0046] Example 2 In vitro experiments confirmed that blocking IL-10 and IL-17 significantly inhibited the promoting effect of Th17 cells on ESC proliferation and invasion

[0047] 1) IL-17A protein promotes the growth and invasion of ESCs in vitro

[0048] The control endometrium tissue, EMS patient eutopic endometrium and ectopic endometrium tissue were collected, digested by IV collagenase (Sigma) and isolated and cultured as primary ESCs, and then stimulated with recombinant human IL-17A protein for 48 hours, respectively. The cell viability of ESC was detected by CCK8 (Dong Ren Chemical Company), Annexin V-FITC / PI double staining (Invitrogen Company) method and Matrigel (BD Company) invasion assay (as shown in Fig. figure 2 As shown in A), apoptosis (such as figure 2 B) and invasiveness (as shown in figure 2 C, shown in 2D), the results showed that recombinant human IL-17A significantly promoted ESC viability, inhibited its apoptosis and promoted its invasion;

[004...

Embodiment 3

[0053] Example 3 The combined application of IL-10 and IL-17 neutralizing antibodies significantly inhibited the growth of ectopic foci in EMS mice Animal experiments

[0054] (1) Construction of EMS mouse model: healthy 7-week-old female C57B / L6 mice (Shanghai Slack Experimental Animal Co., Ltd.), induced with intramuscular injection of estrogen once a week before operation, and then laparotomy under anesthesia to obtain bilateral autopsies The uterus was divided into 4 parts, which were sewed on the four quadrants of the peritoneum respectively. The mice were treated routinely 14 days after the operation, and the EMS mouse model was successfully established (such as Figure 5 shown in A);

[0055] (2) 4 days after EMS mice were modeled, the experimental group was given anti-mouse IL-10 neutralizing antibody, anti-mouse IL-17A neutralizing antibody or a combination of the two antibodies (both antibodies 5ug / ml, total volume 15ul / g), and strengthened once 4 days later, a tota...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the technical field of medicine, and relates to novel pharmaceutical application of interleukin antibodies, in particular to application of interleukin IL-10 and IL-17 antibodies to preparation of a pharmaceutical composition for treating endometriosis. In vitro experiments and in vivo animal experiments show that IL-10 and IL-17A protein recombination can remarkably promote growth and invasion of endometrial stromal cells (ESC), and an IL-10 and IL-17A neutral antibody pharmaceutical composition can remarkably inhibit growth of an ectopic focus. Further, the interleukin antibodies can be used for preparing drugs for treating endometriosis.

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a new medicinal application of an interleukin antibody, in particular to an interleukin is IL-10 and IL-17 antibody used for preparing a pharmaceutical composition for treating endometriosis (endometriosis) use in . In vitro experiments and in vivo animal experiments showed that recombinant IL-10 and IL-17A proteins significantly promoted the growth and invasion of endometrial stromal cells (ESCs); the combination of IL-10 and IL-17A neutralizing antibody drugs significantly inhibited ectopic stove growth. Further, it can be used to prepare medicine for treating endometriosis. [0002] Background technique: [0003] The prior art discloses that endometriosis (abbreviated as Endometriosis, EMS) is a common gynecological disease, manifested by endometrium appearing in other parts (such as ovary, peritoneum, etc.) outside the uterine cavity. The ectopic endometrial tissue undergoes...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61P15/00
CPCC07K16/244A61K2039/505A61K2039/507
Inventor 李明清常凯凯李大金金莉萍邵珺刘立兵
Owner THE OBSTETRICS & GYNECOLOGY HOSPITAL OF FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com